rs869025185
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PM4_SupportingPP5_Very_Strong
The NM_001370259.2(MEN1):c.1087_1089del(p.Glu363del) variant causes a inframe deletion change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. E363E) has been classified as Likely benign.
Frequency
Genomes: not found (cov: 32)
Consequence
MEN1
NM_001370259.2 inframe_deletion
NM_001370259.2 inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 6.98
Genes affected
MEN1 (HGNC:7010): (menin 1) This gene encodes menin, a tumor suppressor associated with a syndrome known as multiple endocrine neoplasia type 1. Menin is a scaffold protein that functions in histone modification and epigenetic gene regulation. It is thought to regulate several pathways and processes by altering chromatin structure through the modification of histones. [provided by RefSeq, May 2019]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 13 ACMG points.
PM1
?
In a hotspot region, there are 3 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 2 benign, 12 uncertain in NM_001370259.2
PM2
?
Very rare variant in population databases, with high coverage;
PM4
?
Nonframeshift variant in NON repetitive region in NM_001370259.2. Strenght limited to Supporting due to length of the change: 1aa.
PP5
?
Variant 11-64805730-ACTC-A is Pathogenic according to our data. Variant chr11-64805730-ACTC-A is described in ClinVar as [Pathogenic]. Clinvar id is 16685.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-64805730-ACTC-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MEN1 | NM_001370259.2 | c.1087_1089del | p.Glu363del | inframe_deletion | 8/10 | ENST00000450708.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MEN1 | ENST00000450708.7 | c.1087_1089del | p.Glu363del | inframe_deletion | 8/10 | 5 | NM_001370259.2 | P3 |
Frequencies
GnomAD3 genomes ? Cov.: 32
GnomAD3 genomes
?
Cov.:
32
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome ? Cov.: 32
GnomAD4 genome
?
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Multiple endocrine neoplasia, type 1 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | May 06, 2021 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with multiple endocrine neoplasia 1 (MIM#131100), and familial isolated primary hyperparathyroidism (PMID: 31263451). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0213 - In-frame insertion/deletion in a non-repetitive region that has high conservation. (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0600 - Variant is located at the MLL1 binding site within the annotated menin domain, forming a stable salt bride (NCBI, PMID: 22936661). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. It has been reported in multiple individuals with multiple endocrine neoplasia type 1 (ClinVar, PMID: 9215689, PMID: 22026581). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Analysis of protein activity has established that this variant causes a reduction in menin protein stability and expression (PMID: 21819486). (SP) 1206 - This variant has been shown to be paternally inherited (19G001331). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 18, 1997 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jul 25, 2023 | This variant, c.1087_1089del, results in the deletion of 1 amino acid(s) of the MEN1 protein (p.Glu363del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with hyperparathyroidism and multiple endocrine neoplasia type 1 (PMID: 9215689, 11454510, 12050235, 22026581). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 16685). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this variant affects MEN1 function (PMID: 21819486). - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 14, 2021 | In-frame deletion of 1 amino acid in a non-repeat region predicted to critically alter the protein; Not observed in large population cohorts (Lek 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Published functional studies demonstrate a damaging effect: decreased menin protein expression and stability (Shimazu 2011); Also known as c.1197_1199delGAG; This variant is associated with the following publications: (PMID: 12050235, 17711922, 9103196, 28193735, 9671267, 21819486, 10730900, 22026581, 11454510, 9354421, 9681840, 10617276, 15281352, 9215689, 29738674, 28881068, 11807402) - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 24, 2024 | The c.1087_1089delGAG pathogenic mutation (also known as p.E363del), located in coding exon 7 of the MEN1 gene, results from an in-frame GAG deletion between nucleotide positions 1087 and 1089. This results in the in-frame deletion of a glutamic acid residue at codon 363. This alteration has been detected in multiple individuals meeting the clinical criteria for a diagnosis of multiple endocrine neoplasia type 1 (Agarwal SK et al. Hum. Mol. Genet. 1997 Jul;6(7):1169-75; Belar O et al. Clin. Endocrinol. (Oxf). 2012 May;76:719-24; Ambry internal data). In another study, this alteration segregated with disease in five family members whose clinical symptoms included: primary hyperparathyroidism, mild hypercalcemia, and parathyroid hormone levels within the upper normal or slightly elevated range (Miedlich S et al. Eur. J. Endocrinol. 2001 Aug;145(2):155-60). In a study analyzing the stability levels of menin protein, this alteratioin was shown to have ~30% menin stability when compared to wild type (Shimazu S et al. Cancer Sci. 2011 Nov;102(11):2097-102). In addition, this alteration is predicted to be deleterious by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the available evidence, this alteration is classified as a pathogenic mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at